Clinical pharmacokinetics of naproxen

被引:118
作者
Davies, NM [1 ]
Anderson, KE [1 ]
机构
[1] UNIV ALBERTA,FAC PHARM & PHARMACEUT SCI,EDMONTON,AB T6G 2N8,CANADA
关键词
D O I
10.2165/00003088-199732040-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Naproxen is a stereochemically pure nonsteroidal anti-inflammatory drug of the 2-arylpropionic acid class. The absorption of naproxen is rapid and complete when given orally. Naproxen binds extensively, in a concentration-dependent manner, to plasma albumin. The area under the plasma concentration-time curve (AUG) of naproxen is linearly proportional to the dose for oral doses up to a total dose of 500mg. At doses greater than 500mg there is an increase in the unbound fraction of drug, leading to an increased renal clearance of total naproxen while unbound renal clearance remains unchanged. Substantial concentrations of the drug are attained in synovial fluid, which is a proposed site of action for nonsteroidal anti-inflammatory drugs. Relationships between the total and unbound plasma concentration, unbound synovial fluid concentration and therapeutic effect have been established. Naproxen is eliminated following biotransformation to glucuroconjugated and sulphate metabolites which are excreted in urine, with only a small amount of the drug being eliminated unchanged. The excretion of the 6-O-desmethylnaproxen metabolite conjugate may be tied to renal function, as accumulation occurs in end-stage renal disease but does not appear to be influenced by age. Hepatic disease and rheumatoid arthritis can also significantly alter the disposition kinetics of naproxen. Although naproxen is excreted into breast milk, the amount of drug transferred comprises only a small fraction of the maternal exposure. Significant drug interactions. have been demonstrated for probenecid, lithium and methotrexate.
引用
收藏
页码:268 / 293
页数:26
相关论文
共 140 条
[51]  
GERARD MJ, 1988, REV RHUM, V55, P735
[52]   STEADY-STATE PHARMACOKINETICS OF NAPROXEN IN ELDERLY RHEUMATICS COMPARED WITH YOUNG VOLUNTEERS [J].
GOTZSCHE, PC ;
ANDREASEN, F ;
EGSMOSE, C ;
LUND, B .
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1988, 17 (01) :11-16
[53]  
GOTZSCHE PC, 1983, SCAND J RHEUMATO S50, V12, P2
[54]   INVIVO PLASMA-PROTEIN BINDING INTERACTION BETWEEN VALPROIC ACID AND NAPROXEN [J].
GRIMALDI, R ;
LECCHINI, S ;
CREMA, F ;
PERUCCA, E .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1984, 9 (04) :359-363
[55]  
GUELEN PJM, 1988, INT J CLIN PHARM TH, V26, P190
[56]  
HARDY JG, 1991, ALIMENT PHARM THERAP, V5, P69
[57]  
HELD H, 1980, ARZNEIMITTEL-FORSCH, V30-1, P843
[58]  
HELD H, 1979, Z RHEUMATOL, V38, P111
[59]   VARIABILITY IN THE RISK OF MAJOR GASTROINTESTINAL COMPLICATIONS FROM NONASPIRIN NONSTEROIDAL ANTIINFLAMMATORY DRUGS [J].
HENRY, D ;
DOBSON, A ;
TURNER, C .
GASTROENTEROLOGY, 1993, 105 (04) :1078-1088
[60]  
HOYERAAL HM, 1993, J RHEUMATOL, V20, P1747